The translational research program, Cancer Therapeutics, at the Winthrop P. Rockefeller Cancer Institute was originally known as the Therapeutic Science program. It recently received a name change and more focused mission emphasizing technology associated with the discovery and development of small molecule drug agents, biological therapies and diagnostic tools.
The program focuses on developing hypotheses and evidence-based translational strategies for improved cancer treatment.
The group’s members have a wide range of expertise and practical experience in developing investigational new drug technology applications and conducting studies and clinical trials. The research in the program is highly collaborative across UAMS, nationally and internationally.
The program’s main goal is the optimization of therapies and technologies that connect the bench to the bedside through the discovery and development of new drugs and diagnostic tools for new cancer targets
The institute is now home to a new dedicated Phase 1 Clinical Trial Unit for cancer clinical trials, giving our scientists a space to directly connect preclinical studies to patient outcomes.
One phase 1 trial currently in progress is a $3.5 million study funded by the National Institutes of Health to study a new way to protect cardiovascular health while treating cancer. Another preclinical drug development project to find a new drug to treat multiple myeloma was recently funded with a $3.6 million gift from the Riney Foundation.